ABSTRACT: Traumatic brain injury (TBI) is a leading cause of disability and death from trauma to central nervous system (CNS) tissues. For patients who survive the initial injury, TBI can lead to neurodegeneration as well as cognitive and motor deficits, and is even a risk factor for the future development of neurodegenerative disorders such as Alzheimer's disease. Preclinical studies of multiple neuropathological and neurodegenerative disorders have shown that lithium, which is primarily used to treat bipolar disorder, has considerable neuroprotective effects. Indeed, emerging evidence now suggests that lithium can also mitigate neurological deficits incurred from TBI. Lithium exerts neuroprotective effects and stimulates neurogenesis via multiple signaling pathways; it inhibits glycogen synthase kinase-3 (GSK-3), upregulates neurotrophins and growth factors (e.g., brain-derived neurotrophic factor (BDNF)), modulates inflammatory molecules, upregulates neuroprotective factors (e.g., B-cell lymphoma-2 (Bcl-2), heat shock protein 70 (HSP-70)), and concomitantly downregulates pro-apoptotic factors. In various experimental TBI paradigms, lithium has been shown to reduce neuronal death, microglial activation, cyclooxygenase-2 induction, amyloid-β (Aβ), and hyperphosphorylated tau levels, to preserve blood-brain barrier integrity, to mitigate neurological deficits and psychiatric disturbance, and to improve learning and memory outcome. Given that lithium exerts multiple therapeutic effects across an array of CNS disorders, including promising results in preclinical models of TBI, additional clinical research is clearly warranted to determine its therapeutic attributes for combating TBI. Here, we review lithium's exciting potential in ameliorating physiological as well as cognitive deficits induced by TBI.
T raumatic brain injury (TBI), defined as damage to brain tissue by mechanical force or blunt force trauma, is the primary cause of morbidity and death in young adults in industrialized countries.
1 TBI is also recognized as the "signature wound" of soldiers engaged in the Iraq and Afghanistan wars; since 2001, over 200 000 United States military personnel have sustained TBI. In addition, TBI afflicts an average of 1.7 million people annually in the United States, underscoring its importance as a significant public health concern with long-term personal and economic consequences. Of continuing concern, no FDA-approved drug is presently available for intervention in TBI despite intensive research efforts over the past decades. This dearth of treatment options is at least partly due to the complex pathophysiology of TBI. Specifically, TBI comprises an initial primary injury that mechanically damages neurons, glia, and vascular structures, then is often followed by a cascade of secondary injuries whose onset occurs hours or days after the initial trauma.
3−6 These secondary brain injuries, which are often reversible, may include oxidative stress via free radical formation and lipid peroxidation; excitotoxicity via excess glutamate release, increased N-methyl-D-aspartate (NMDA) receptor activation that may result in increased calcium ion influx; neuroinflammation via proinflammatory cytokines, nitric oxide, or prostaglandins; mitochondrial disruption involving increased poly[ADP-ribose] polymerase 1 (PARP-1) activation, decreased NAD + /ATP levels, increased calpain activation, and permeabilization of mitochondrial permeability transition pore (mPTP); failure of the blood-brain barrier involving cerebral edema, hypoxia, and ischemia; and cellular death via necrosis, caspase-dependent (caspase-3) apoptosis, and caspase-independent (apoptosis Special Issue: Current Hypotheses of Lithium's Mechanism of Action as a Neuropsychiatric Medication inducing factor) apoptosis. 3, 4, 7 Sequelae such as neuropsychiatric disturbances (e.g., depression, anxiety, and posttraumatic stress disorder) and behavioral and cognitive deficits typically accompany secondary injuries (for a review, see ref 8) . This complex pathophysiology may therefore require pharmacological agents that act either alone or in concert on multiple cell survival and cell death pathways. 9 Notably, over the past decade and a half, research has clearly shown that lithium, and perhaps valproate, may be able to act in this manner.
The mood stabilizers lithium and valproate have historically been used to treat bipolar disorder. Given that these mood stabilizers act across multiple pathways, it is not surprising that recent research has highlighted their putative use as neuroprotective agents in a variety of neurological and neurodegenerative disorders, including cerebral injury. Here, we present a brief overview of some of lithium's known mechanisms of action, and then review its potential use as a therapeutic agent for the neurological deficits and damage caused by TBI.
■ LITHIUM: MECHANISMS OF ACTION
Evidence from Bipolar Disorder (BD). For over 100 years lithium, has been used in the treatment of manic depression, 10 and as the treatment of choice for BD for over 60 years. Gerrod described the use of lithium in 1859 for the treatment of rheumatic conditions and gout, based on the prevailing hypothesis of the time because of lithium's ability to dissolve nitrogen-containing compounds such as uric acid which were believed to accumulate in tissues, thus resulting in illnesses. In the 1880s, Carl Lange and others used lithium in the treatment of BD, and by 1885 lithium carbonate and citrate had earned a place in the British Pharmacopoeia. The urea hypothesis was also used as rationale for the use of lithium in food stuffs and tonics, most notably with the introduction in 1929 of "BibLabel Lithiated Lemon-Lime Soda", later to be renamed "7 UP". Due to the decline of the urea hypothesis and a lack of a credible therapeutic mechanism, the lithium was subsequently removed by 1950 (summarized in ref 11) .
Working with BD patients, John Cade rediscovered the use of lithium in 1949. 12 Based on the hypothesis that BD was caused by toxins which were thought to be recoverable in urine, he identified urea as the most toxic compound, and reasoned that alkali metal injections could dissolve the toxin. He then found that lithium caused sedation and stupor in test animals, suggesting to him that it may have mood-control properties. Testing lithium on himself and then with BD, depressed, and schizophrenic patients, he found great improvements in the BD group (summarized in ref 11).
In the treatment of BD, typically, lithium is effective in approximately one-third of patients, partially effective in another third, and not effective in the remainder; exciting new data are emerging suggesting that some forms of nonresponsiveness to lithium treatment may be due to variants in the promoter of the glutamate decarboxylase-like protein 1 (GADL1) gene. 13 Lithium's mechanisms of action in BD are numerous and complex, and it is beyond the scope of this article to review exhaustively. The interested reader is directed to several articles addressing this topic. 14−21 One particularly intriguing, although debated, area of research in BD stems from the observation that gray matter increases are associated with lithium treatment. 16 Magnetic resonance imaging of BD patients treated with lithium showed higher concentrations of N-acetyl-aspartate (NAA) (a marker of neuronal integrity) that is typically otherwise suppressed in BD. 22, 23 BD patients treated with lithium, however, displayed an increased number of neurons (greater volume with higher density of gray matter) relative to patients not treated with lithium and healthy controls. 16 A voxel-based morphometric comparative study found that BD-I patients receiving lithium had significantly lower gray matter volumes in the left middle temporal gyrus and larger gray matter volumes in the left parahippocampal gyrus. 24 Earlier studies comparing juvenile BD patients and healthy controls reported that untreated BD patients had lower amygdalar gray matter volumes compared to those treated with lithium or valproate. 25 BD patients also exhibited decreased gray matter in amygdala and prefrontal cortex and hyper-intensity of white matter. 26 Other studies of BD patients found that lithium treatment significantly increased cortical gray matter density, most notably in the cingulate and paralimbic cortices, regions necessary for attention, motivation, and emotional modulation. Gray matter density increase was also noted in the right anterior cingulate. 27 Finally, a longitudinal brain imaging study noted that lithium-induced increases in gray matter volume correlated with treatment response in BD subjects. 28 Despite these multiple, intriguing findings, a recent report suggested that lithium-induced gray matter increase could be artifactual and actually stem from changes in MRI signal characteristics. 29 Other approaches such as quantification of synaptic density and related neuropil may help resolve this question.
Glycogen Synthase Kinase-3 (GSK-3) Inhibition and Transcription Factor Activation. GSK-3 exists in two structurally similar isoforms, α and β, which share 85% sequence homology. 30 Although GSK-3α and GSK-3β are highly homologous within their kinase domains and display similar biochemical and substrate properties, their functional roles are not always identical. For example, the transcription factors early growth response 1 and Smad3/4 are oppositely affected by GSK-3α and GSK-3β. 31 In addition, GSK-3β plays a more important role than GSK-3α in mediating spontaneous neuronal death in extended cultures. 32 Lithium directly inhibits GSK-3 by binding to the magnesium-sensitive site of the enzyme, 33, 34 and indirectly inhibits GSK-3 by enhancing phosphorylation to specific serine residues. The first evidence that lithium indirectly inhibits GSK-3 came from studies noting its ability to act on the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway and elevate phosphorylation of GSK-3α at Ser21. 35 Lithium can also indirectly inhibit the GSK-3β isoform by phosphorylation at Ser9. 36 It was further shown to increase GSK-3 serine phosphorylation by disrupting β-arrestin 2/ protein phosphatase 2A/Akt complex formation, which dephosphorylates and inactivates Akt. 37 Phosphorylation of GSK-3 by activating upstream Akt and protein kinases A or C (PKA, PKC) then can result in effects on diverse biological processes (for a review, see refs 15−19, 36, and 38−43) . Notably, GSK-3 can phosphorylate various nuclear factors such as Wnt/β-catenin and nuclear factor of activated T cells (NFAT) (for a review, see refs 16 and 39) . In addition, lithium by inhibiting GSK-3 can also activate the transcription factors activator protein-1 (AP-1) and cyclic AMP-response element binding protein (CREB), 44 as well as the mitogen-activated protein (MAP) kinase pathway; 45 for a review, see ref 17 . GSK-3 also has the ability to promote self-activation through enhancing phosphatase activity which removes its own Nterminal inhibitory phosphate groups, 46 as well as through Lithium can block both of these mechanisms as part of its role in GSK-3 inhibition. 48 Thus, in light of its central role in signaling, GSK-3 may be considered as a major way station in mediating lithium's actions with effects in major systems such as anti-inflammation by suppressing IL-6 production and astrocyte activation; 49 neuroprotection by stimulating antiapoptotic factors including CREB, HSF-1, NF-κB, and β-catenin and eventually B-cell lymphoma 2 (Bcl-2) (for a review, see refs 39 and 50); and the alleviation of depressive behaviors in experimental animals. 41,51−55 Indeed, lithium has even been shown to attenuate amphetamineinduced hyperlocomotion behavior via Akt kinase activity in a mouse model. 56 Neuroprotection. Lithium has been shown to be highly neuroprotective in numerous in vivo and in vitro models, and to prevent neuronal apoptosis via multiple mechanisms (for a review, see refs 14−16 and 18). Pioneering studies found that chronic (6−7 days) lithium treatment at therapeutic concentrations provided nearly complete protection against glutamateinduced excitotoxicity in primary cerebellar, cerebral cortical, and hippocampal neuronal cultures; these neuroprotective effects occurred independently of lithium-mediated inositol monophosphatase activity blockade, but were associated with downregulation of NMDA receptor-mediated calcium influx 57,58 due to lithium-induced Src kinase inactivation and resulting inhibition of the NR2B subunit tyrosine phosphorylation. 59 It is currently unknown whether this aspect of lithium's action requires GSK-3 inhibition. These neuroprotective effects also stimulated cell survival factors, such as BDNF/TrkB, 60 antiapoptotic Bcl-2, and heat shock protein 70 (HSP70) in a GSK-3 dependent manner. 18 Concomitantly, lithium was found to inhibit p38 kinase, AP-1 DNA binding activity, and glutamate-induced JNK activity, as well as induce the loss of phosphorylated CREB by reducing protein phosphatase 1 and increasing MEK activities. 61 This suggests that CREB and CRE-responsive genes such as Bcl-2 may be a mechanism for lithium's effects on neuronal survival. Notably, lithium also inhibited pro-apoptotic molecules such as p53 and Bax; 62 pretreatment with lithium inhibited glutamate-induced mitochondrial cytochrome c release, activation of caspse-3, as well as cleavage of lamin B1, which is the nuclear substrate for caspase-3, a critical enzyme that mediates apoptosis.
Lithium can also increase the activity of the antiapoptotic serine-threonine Akt-1 kinase and its upstream PI3K in primary cerebellar neurons. 35 Cerebellar neurons cultured with serum respond with higher levels of phosphorylated/active Akt-1. The PI3K inhibitors wortmannin and LY294002 blocked Akt-1 activity causing neuronal death, and this neuronal apoptosis was prevented by chronic lithium exposure. PI3K activity as well as Akt-1 phosphorylation and kinase activity were rapidly, but transiently, increased by lithium, thus reversing glutamateinduced loss of Akt-1 activity and cell viability. Acute lithium exposure also protected cortical neurons via a PI3K-mediated increase in intracellular calcium through the phospholipase Cγ pathway. 63 Furthermore, in cultured human neuroblastoma SH-SY5Y cells, lithium treatment ameliorated HIV-gp120-mediated toxicity via the PI3K/Akt pathway. 64 In addition, GSK-3 inhibitorsincluding lithiumhave been shown to control inflammatory conditions in both the peripheral and central nervous systems. For example, an in vitro study found that lithium significantly increased both proinflammatory (IFN-γ, TNF-α, IL-8) and anti-inflammatory immunoregulatory cytokines/compounds (IL-10, IL-1 receptor antagonist). 65 With regard to pro-inflammation, lithium can increase TNF-α in Raw264.7 macrophages and modulate differential signaling depending on Toll-like receptor 2/3 stimulation. 66 With regard to anti-inflammation, lithium pretreatment in an experimental autoimmune encephalomyelitis (EAE) mouse spinal cord study abolished the onset of EAE and markedly decreased demyelination, microglial activation, and leukocyte infiltration. 67 Also, in a rodent TBI model, lithium robustly suppressed injury-induced associated microglia activation (see below).
As the above evidence highlights, the effects of lithium on cellular systems are indeed far reaching. An earlier microarray analysis using neuroblastoma SH-SY5Y documented that lithium elicited over 900 statistically significant gene expression changes and, in particular, the Six1 gene mediated lithium protection against staurosporine-induced apoptosis by blockade of caspase-3 activation. 68 A recent microarray analysis found that lithium differentially regulated the expression of over 50 genes including basic transcription factors, transcription activators, cell signaling proteins, cell adhesion proteins, oncogenes and tumor suppressors, intracellular transducers, survival and death genes, and cyclins. 69 In another recent microarray study using rat cerebellar granule cells and SH-SY5Y cells, lithium and valproate combination was found to be protective against glutamate excitotoxicity and the neuroprotection was associated with downregulation of a prominent microRNA, miR-34a. 70 Neurotrophins and Growth Factors. The effects of lithium on neurotrophin expression are numerous, and may depend on brain state, region, and species (for a review, see ref 16 ) Depression has been reported to reduce brain levels of BDNF, 71, 72 and lithium is known to increase BDNF levels in the brain. 72−75 Lithium and valproate both selectively activated BDNF promoter IV of primary neurons 76 and elevated BDNF levels in rat hippocampal, frontal, and temporal cortices, 77, 78 but not the mouse thalamus. 79 Acute and long-term lithium treatment were both found to increase the BDNF receptor TrkB in the mouse anterior cingulate but not in the hippocampus, while acute lithium significantly reduced CREB phosphorylation, an important intracellular target of TrkBmediated signaling. 80 This decrease in CREB phosphorylation is in contrast to an increased phospho-CREB level reported previously in an in vivo and in vitro study following lithium treatment, 44 and the discrepancy may stem from differences in the experimental conditions such as the duration of drug treatment and brain regions examined. These above-mentioned findings support the suggestion that BDNF release and receptor activation can be increased by lithium. One study even found that certain BDNF polymorphisms can predict response to lithium in patients with bipolar depression, 81 and a clinical trial in patients with Alzheimer's disease found that lithium increased serum BDNF levels, and that this was accompanied by reductions in cognitive impairment. 82 Interestingly, lowered levels of BDNF have been reported in BD patients, 83 and lithium treatment has also been found to restore and even increase these levels. 84−86 Additionally, in a study using peripheral blood mononuclear cells, hypermethylation (which block transcription factor binding ultimately leading to gene silencing) of the BDNF promoter region was found in BD II patients, and lithium significantly reduced this DNA methylation. 87 However, these findings are not without debate, as other studies found lithium to lower BDNF levels in BD patients. 88 Together, the data support that BDNF induction and secretion could be one mechanism by which lithium exerts its neuroprotective effects.
Lithium also has been reported to increase nerve growth factor (NGF) in the rat frontal cortex, hippocampus, amygdala, and limbic forebrain. 73,74,89−91 However, no effects were noted on NGF levels in the striatum, hypothalamus, or midbrain. 90 Neurotrophin-3 (NT-3) levels in the serum and hippocampus of rats were elevated by lithium after amphetamine-induced mania regardless of whether lithium treatment was initiated before, simultaneously, or after amphetamine treatment; 92 95) , and promoting development, cell survival, proliferation, migration, and permeability. 96, 97 In this respect, VEGF acts as a direct neurotrophic/neuroprotective factor both in vivo and in vitro. 98−101 Multiple reports have confirmed that TBI increases the expression of VEGF and its receptor, 102,103 supporting angiogenesis and astrogliosis. 104, 105 In a mouse TBI model, lateral ventricle infusion of VEGF increased the number of astrocytes, oligodendroglia, and some neurons. Furthermore, lesion size was decreased, and significant improvement of functional outcome was observed.
106−108
Recent studies using an ischemic paradigm in rats found that the mood stabilizer valproate could enhance angiogenesis and promote functional recovery by upregulating VEGF through hypoxia-inducible factor-1α (HIF-1α). 109 Earlier preclinical models of TBI had found that lithium was neuroprotective against induced stroke in both rats 110−112 and mice.
113−115
Expanding on previous investigations which showed that lithium increased VEGF expression, 116−118 an in vitro study under serum-deprivation conditions using human brain microvascular endothelial cells and primary rat cortical astrocytes found that lithium promoted VEGF through a PI3K/GSK-3β-dependent pathway in brain endothelium, but through a PI3K/ GSK-3β-independent pathway in astrocytes. 119 Together, these data support the notion that lithium's neuroprotective effects, including those observed in mouse models of TBI (see below), may be at least partly mediated by VEGF, similar to the neuroprotective effects of valproate.
Fibroblast growth factor-21 (FGF-21), a new member of the FGF superfamily, is a recently discovered metabolic regulator involved in glucose and lipid metabolism. 120 It targets the liver, pancreatic islets, and adipose tissue, 121 and is a possible therapeutic target for diabetes and obesity. FGF-21 transcripts have also been detected in the human prefrontal cortex 122 (BrainCloud, www.braincloud.jhmi.edu). Earlier studies found that cotreatment with lithium and valproate could synergistically enhance GSK-3 inhibition over that of lithium alone, 123 as well as prevent glutamate excitotoxicity in aging primary neurons. In a very recent rat model study, mRNA microarray strategy and quantitative real time PCR (q-PCR) were used to demonstrate for the first time that FGF-21 is expressed in primary brain neurons, and that lithium increases FGF-21 mRNA and protein expression levels via GSK-3 inhibition. 124 That study also found that FGF-21 is selectively and synergistically elevated by cotreatment with lithium and valproate via enhanced lithium-induced GSK-3 inhibition and Akt-1 activation, as well as valproate-induced histone deacetylase (HDAC) inhibition. 124 In this proposed complex pathway, the lithium-valproate combination induces Akt-1 to act as an upstream regulator of FGF-21 expression as well as a downstream mediator for FGF-21-induced neuroprotection. 124 Considered together, these novel results indicate that FGF-21 is an important mediator of the protective effects of these mood stabilizers, and holds great promise as a new therapeutic target for CNS disorders, including TBI and others with an underlying excitotoxic component.
Neurogenesis. Numerous preclinical studies have found that lithium induces neurogenesis (for a review, see ref 16) . In a rodent quinolinic acid-induced striatal injury model, short-term lithium exposure activated neurogenesis; the proliferating cells showed astroglial and neuronal phenotypes, suggesting that the newly formed cells were neural stem cells. 125 In other studies, chronic lithium treatment increased neurogenesis in the hippocampus of the rat dentate gyrus; 126, 127 however, in older rats, it enhanced long-term potentiation but not neurogenesis. 128 Lithium also selectively increased differentiation of hippocampal neural progenitor cells both in vitro and in vivo. 129 Insight into the potential mechanisms by which lithium can induce neurogenesis has advanced considerably. It was noted that lithium could prevent stress-induced reductions in VEGF levels and this, as previously mentioned, can stimulate both neurogenesis and angiogenesis. 118 In rats, chronic mild stress led to decreased hippocampal cell proliferation; this type of stress could increase GSK-3β mRNA expression and total GSK-3β protein expression. 130 Lithium could block the negative effects of chronic-mild stress, suggesting that GSK-3β inhibition is involved in preventing the negative effects of stress on behavior and cellular processes. However, another study using chronic stress found that GSK-3β levels did not increase in mouse hippocampus, but rather that phosphorylated levels of GSK-3β decreased, thus indicating enhanced GSK-3β activity (see supplementary material in ref 54) . Other studies found that lithium increased proliferation of adult hippocampal progenitor cells that involved Wnt/β-catenin activation due to GSK-3β inhibition. 131 Lithium at therapeutically relevant concentrations was shown to stimulate the proliferation of nestin-positive progenitor cells in cultured brain neurons. 132 Using an in vitro adult rat spinal cord model, lithium was also found to enhance proliferation and neuronal production of neural progenitor cells after transplantation. Specifically, lithium treatment increased the number of labeled neurons derived from transplanted cells, thus increasing neurogenesis while reducing microglia and macrophage activation. 133 Acting through the PI3K/Akt pathway as a "gain control", lithium upregulated the signaling of the developmental gene Notch in hippocampal neurons as well as in primary T cells or Chinese hamster oocytes. 134 In addition, an earlier report showed that lithium was found to disinhibit Notch by phosphorylating GSK-3β, which prevents GSK-3β activation and the resulting Notch inhibition. 
■ INROADS TO THE FUTURE: LITHIUM IN TBI
The devastating effects of TBI on those afflicted are further amplified by the fact that there are as yet no specified treatment options. However, there is hope for the future treatment of both the primary and secondary injuries associated with TBI. Lithium is already known to ameliorate edema by repairing blood-brain-barrier disruption (see below); prevent inflammation by inhibiting microglia activation and COX-2 induction; protect neurons by preventing excess NMDA receptor activation and calcium influx; stabilize mitochondria via a Bcl-2 dependent mechanism; 136 reduce mitochondrial release of cytochrome c and apoptosis-inducing factor as well as reduce calpain and caspase-3 activation. 137 Furthermore, lithium can reduce cognitive impairments by decreasing APP overexpression and Aβ accumulation, as well as reduce BACE1-injury induced upregulation and tau hyperphosphorylation (see below).
In cases of mild TBI in mice, 30 min of pretreatment with lithium alleviated depressive behavior measured 24 h postinjury. 138 Mild TBI stimulated hippocampal Akt phosphorylation (hence activation) as well as phosphorylation at Ser9 of GSK-3β (hence inhibition) and accumulation of downstream β-catenin. This suggests that one of lithium's effects is to activate this protective pathway, and that GSK-3β inhibition may be a therapeutic target in TBI treatment. In addition, in a mouse model using controlled cortical impact to produce moderate TBI, 14-day pretreatment with lithium attenuated IL-1β expression, brain edema, hippocampal neurodegeneration, and loss of hemispheric tissues, as well as improved memory and spatial learning. 139 Most notably, postinsult injections with therapeutic doses of lithium similarly exerted a marked neuroprotective effect when administered three to 6 h after controlled cortical impactinduced TBI. Specifically, lithium reduced lesion volume when measured 3 days and 3 weeks after injury induction in mice. 113 TBI-induced neuroinflammation detected by microglial activation and cyclooxygenase-2 (COX-2) induction were also reduced, while blood-brain barrier integrity was maintained through inhibition of matrix metallopeptidase-9 (MMP-9) expression. Behaviorally, TBI-induced hyperlocomotor activity, anxiety-like behavior, and impairments in motor coordination were all normalized. In addition, GSK-3β Ser9 phosphorylation was robustly increased, again suggesting that GSK-3β inhibition is involved in mediating lithium's therapeutic effects. 113 Another controlled cortical impact study using lithium starting 30 min postinjury for 5 days also found increased GSK-3β Ser9 phosphorylation with subsequent β-catenin accumulation and reduced neuronal loss in the hippocampal CA3 region, as well as decreased hippocampal-dependent deficits in learning and memory in the period 14−28 days after initial injury. 140 Furthermore, a selective GSK-3 inhibitor, SB-216763, partially mimicked the behavioral benefits of lithium, lending further support to the notion that lithium protects against TBI via GSK-3 inhibition. 140 A very recent study using a rat diffuse severe brain injury model showed that combination treatment with lithium and etanercept, a TNFα inhibitor, decreased TNFα and glial fibrillary acidic protein (GFAP) levels, and alleviated neuronal degeneration, edema, and axonal swelling. 141 Increasing evidence suggests that TBI is a major risk factor in the eventual development of Alzheimer's disease (for a review, see ref 142) . Animal models as well as patient populations afflicted by TBI show increased memory impairment. 143 Elevated levels of amyloid-β (Aβ) have also been found in the cerebrospinal fluid 144, 145 and post-mortem brain samples of TBI patients. 146, 147 Interestingly, GSK-3 hyperactivity has been implicated in the pathogenesis of Alzheimer's disease by regulating amyloid precursor protein (APP) cleavage and thus increasing Aβ production. 148, 149 Lithium as a GSK-3 inhibitor can counteract increased Aβ production and can therefore produce beneficial effects in various Alzheimer's disease models (for a review, see refs 15−17). In addition, previous research found that lithium could protect cultured PC12 cells from Aβ42 toxicity, a more toxic form of Aβ comprising 42 amino acids, possibly by upregulating Bcl-2. 150 Indeed, reducing Aβ by inhibiting β-or γ-secretase enzyme processing of APP, or by modulating ATP binding cassette protein A1 (ABCA1, which enhances Aβ clearance), were found to have beneficial effects including protection of hippocampal tissue. 151, 152 These results suggest that postinsult lithium treatment may be a rationale strategy to alleviate Alzheimer's-disease-like syndromes associated with TBI.
In recent studies testing the above-mentioned hypothesis using a mouse controlled cortical impact TBI model, 1.5 mEq/ kg lithium i.p. given 15 min post injury and then once daily thereafter robustly reduced TBI-induced APP increases, β-APPcleaving enzyme-1 (BACE1) overexpression, Aβ load in the hippocampus and corpus callosum, tau hyperphosphorylation in the thalamus, and significantly preserved brain tissues. 114 One group reported that a 27-kDa Aβ oligomer, which had previously been shown to be toxic, 153 was robustly elevated by TBI, and this increase was attenuated by lithium. 114 APP and Aβ42 levels were also elevated in the hippocampus by TBI, as well as in axonal bulbs of the corpus callosum; again, lithium significantly reduced these increases. Most notably, Y-maze and Morris water maze tests showed that lithium mitigated memory and spatial learning deficits induced by TBI, which were associated with suppression of TBI-induced loss of hippocampal volume. 114 Moreover, lithium-induced downregulation of APP accumulation, Aβ generation, and tau hyperphosphorylation through GSK-3 inhibition has been reported in a transgenic mouse model of Alzheimer's disease, 154 and GSK-3 inhibitor-mediated inhibition of BACE1 activity was also reported. 155 This evidence readily supports the notion that lithium, by reducing levels and processing of APP as well as levels of tau phosphorylation (most likely via GSK-3 inhibition) can reduce TBI-induced Aβ load and tau hyperphosphorylation and mitigate the resulting negative downstream effects, notably learning and memory deficits. 113, 114, 140 Figure 1 illustrates the proposed pathophysiological events induced by lithium after TBI.
In a very recent expansion of these experiments, subeffective doses of combined lithium and valproate were more useful in mitigating TBI injury than either agent used alone. 115 Previous studies had found that cotreatment with lithium and valproate could synergistically enhance GSK-3 inhibition over that of lithium alone, and prevent glutamate excitotoxicity in aging primary neurons. 123 Previous work also found that epigenetic regulation via HDAC inhibition, which restores histone acetylation levels and corrects transcriptional deficits, is neuroprotective in TBI and other brain disorder models, including maintenance of blood-brain barrier integrity, reduction of contusion volume, and improvement of spatial memory and motor function.
156−161 Lithium (1 mEq/kg) and valproate (200 mg/kg) cotreatment was administered i.p. 15 min after TBI, and then once daily thereafter. At 3 days postinjury, cotreatment significantly reduced lesion volume, attenuated blood-brain barrier disruption, mitigated hippocampal neurodegeneration, and robustly increased histone H3 acetylation (an index of HDAC inhibition). Additionally, starting from seven to at least 21 days postinjury, motor coordination was improved as measured by the decrease in number of foot faults in a beam-walk test. As expected, treatment with either of these mood stabilizers alone at subeffective doses had no benefit against TBI. 115 These findings are the first experimental evidence showing that cotreatment with subeffective doses of lithium and valproate can significantly reduce brain tissue damage and protect bloodbrain barrier integrity from TBI. These benefits are associated with a synergistic increase in acetylated-histone H3 levels, suggesting a cross-talk between GSK-3 and HDAC inhibition. This pharmacological strategy may be a promising route for therapy in that lower doses can avoid undesirable side effects, particularly kidney and thyroid toxicity from lithium, and liver toxicity from valproate. 15 In light of the possibility of inducing lithium toxicity, routine monitoring of blood levels should still be done to avoid unwanted side effects.
It should be noted that previous studies have also documented that combining lithium and valproate treatment provided more beneficial effects with regard to preventing excitotoxicity of neuronal cultures, and improved outcome in mouse models of amyotrophic lateral sclerosis (ALS) and Huntington's disease than monotreatment with either drug. 123, 162, 163 Moreover, it was found that in a model of rat brain ischemia, copriming mesenchymal stem cells (MSC) with these two mood stabilizers increased homing and migration of MSCs to the lesion site and improved functional outcome. 164, 165 Together, these preclinical studies suggest that combined therapy with lithium and valproate may be a rational strategy for ameliorating the neuropathology associated with CNS disorders including TBI.
Lithium's Effects on Glia. Much of the research into the protective and regenerative properties of lithium has focused on neurons; in contrast, limited research has been conducted into lithium's effects on white matter, which also plays an important part in TBI-related pathophysiology (for a review, see ref 166) . Very early post-mortem studies of patients afflicted by a demented state after experiencing TBI showed diffuse degeneration of cerebral white matter, 167 and more modern studies using MRI showed white matter decrease after mild TBI. 168 Recent studies using immunofluorescence staining have shown that increases in white matter microglia/macrophages correlate with the severity of TBI injury. 169 Another study using diffusion tensor imaging in a rat model found that repetitive TBI significantly increased microstructural damage to white matter. 170 Moreover, a review of imaging studies found that after the initial and secondary injury periods, pathological changes showed greater disruption to white matter neural connectivity. 171 Studies that administered clinical doses of lithium in a rat spinal cord injury model found that it resulted in significant corticospinal and serotonergic axon sprouting and promoted locomoter functional recovery. 172 Interestingly, patients suffering from BD may show white matter disruption, and a diffusion tensor imaging study of individuals with BD found that lithium improved white matter structure and functional integrity in multiple brain areas. 173 In addition, a rat ischemic model using delayed (24 h postinjury) valproate treatment found increased oligodendrocyte survival as well as an increased number of newly generated oligodendrocytes. 174 These model systems demonstrated the efficacy of using lithium and valproate to rescue, repair, and even regenerate white matter. Future investigations of lithium in white matter protection after TBI are clearly warranted.
■ CONCLUSION
In summary, recent preliminary data using lithium have demonstrated robust beneficial effects in experimental models of TBI. These include decreases in TBI-induced brain lesion, suppression of neuroinflammation, protection against bloodbrain barrier disruption, normalization of behavioral deficits, and improvement of learning and memory, among others. These exciting findings raise the possibility that the mood stabilizers lithium and valproate, either alone or in combination, may be repurposed as drugs that can be used in clinical settings to treat multiple categories of neuropathological, neurodegenerative disorders including those with an excitotoxic component, such as acute ischemia and TBI. In addition, because of their long history of safe clinical use, and the recently discovered synergistic effects stemming from cotreatment, thus requiring lower doses that, in turn, would result in fewer side effects and improved tolerability, future investigation is clearly warranted both in the laboratory and in clinical settings. 
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